American Association of Clinical Endocrinology

06/18/2025

This case includes the use of alpelisib for long-term treatment of tumor-induced hypoglycemia in 2 patients with insulin-producing or proinsulin-producing tumors.

Tumor-induced hypoglycemia (TIH) is a rare and often fatal complication of cancers that produce or induce secretion of hormones such as insulin, insulin-like growth factor 2, and proinsulin. We present a case series describing the effectiveness and tolerability of the phosphatidylinositol 3-kinase i...

06/18/2025

AACE is pleased to announce a significant increase in the Journal Impact Factor for our flagship journal, Endocrine Practice, reaching 4.6 in the new Journal Citation Reports (JCR) from Clarivate published today. This is a 24% increase from last year's Impact Factor of 3.7. Read the latest issue of Endocrine Practice: https://www.endocrinepractice.org/current

06/18/2025

This study found several non-LDL cholesterol markers as risk-enhancing markers of cardiovascular disease.

To review existing and new evidence regarding the relationship between diabetes and dyslipidemia and to provide an update of the lipid biomarkers used to assess cardiovascular risk and the current guidelines reflecting these changes.

06/18/2025

The Inpatient Diabetes Certificate is a comprehensive program that prepares healthcare professionals to effectively manage diabetes and hyperglycemia in hospitalized patients. Learn more and register: https://pro.aace.com/education-and-event/product/aace-certificate-inpatient-diabetes

06/17/2025

Learn how Rajesh Garg, MD, and his team at Harbor-UCLA Medical Center’s Diabetes Clinic improved vaccination rates from 0% to 100% by integrating efficient, team-based workflows. Their approach shows how small changes can drive sustainable improvements in diabetes care for underserved populations.

06/17/2025

A better understanding of the etiology and proper management of this condition may improve early detection and clinical outcomes in affected patients.

Central hypothyroidism is a rare disorder resulting from impaired thyroid hormone production due to deficiencies in TSH secretion from the pituitary or TRH secretion from the hypothalamus. This review aims to summarize recent advances in the etiology, diagnosis, and treatment of central hypothyroidi...

06/17/2025

Gain practical experience through interactive case studies. The Obesity and Weight Loss Certificate Program provides healthcare professionals with in-depth knowledge and practical tools to manage and treat obesity and its related health conditions. Learn more and register: https://pro.aace.com/education-and-event/product/aace-certificate-fundamentals-obesity-weight-loss

06/16/2025

Unlock the skills and knowledge necessary to effectively diagnose, treat, and manage osteoporosis with our comprehensive course designed for healthcare professionals. Register today: https://pro.aace.com/education-and-event/product/bridging-gap-comprehensive-osteoporosis-care-primary-practice

06/16/2025

Shortages of name-brand obesity drugs sparked a surge in online sales of compounded alternatives. In a recent NPR report, AACE President Scott Isaacs, MD, Endocrinologist and Weight Loss Specialist, expressed concern about these products, warning that they have not been proven safe or effective. Without FDA oversight, there's no guarantee that these actually work, and there can be dosing errors.

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.

06/16/2025

This study demonstrates that Freestyle Libre 2 and 3 significantly improves glycemic control in hospitalized patients with type 2 diabetes.

To determine the effect and safety of continuous glucose monitoring (CGM) use in glycemic control compared to standard approach in hospitalized patients with type 2 diabetes.

06/13/2025

A case of delayed-onset hypothyroidism following discontinuation of the combination lenvatinib-pembrolizumab.

Lenvatinib and pembrolizumab are emerging agents being used for various malignant tumors with antitumor activity and an acceptable safety profile. However, monotherapy with these immunotherapies can lead to various endocrinopathies, which raises an important question—whether the combination increa...

06/13/2025

📢 Just Launched! AACE Endocrinology and Diabetes (AED)
Now available! AACE’s open access journal. AED accepts original research, reviews, case reports, visual and video vignettes. Read the editorial by Editor-in-Chief, Dr. Vin Tangpricha:
https://www.endocrinologydiabetes.org/article/S3050-9157(25)00022-0/fulltext